Received Apr 21, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MEN | MENINGOCOCCAL (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | U7616AB | OT / RA |
expired vaccine administration with no reported adverse event; Initial information received on 16-Apr-2025 regarding an unsolicited valid non-serious case received from a nurse. This case involves a 18 years old female patient who received expired meningococcal A-C-Y-W135 (T CONJ) vaccine [Menquadfi] with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications included covid-19 vaccine; influenza vaccine; and hepatitis B vaccine, all for Immunisation. On 16-Apr-2025, the patient received 0.5 ml of suspect meningococcal A-C-Y-W135 (T CONJ) vaccine Solution for injection of standard strength once with lot U7616AB and expiry date 11-Apr-2025 via intramuscular route in the right deltoid for immunisation (expired product administered) (Latency same day) Action taken was not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
COVID-19 VACCINE; INFLUENZA VACCINE; HEPATITIS B VACCINE